efficacy of glp 1 receptor agonists glucagon-like peptide-1 for prevention of stroke among patients with and without diabetes: A meta-analysis with the SELECT and FLOW trails Glucagon-like peptide 1 receptor agonists

There is no indication that GLP-1s have negatively impacted medtech volumes or pricing

Transition to Metabolic Constraint Collectively, GLP-1RA therapy is characterized by persistent reductions in nutrient inflow, increased reliance on lipid-derived substrates, suppression of anabolic pathways through AMPK signaling, and context-dependent modulation of adipose tissue lipolysis

Prescriptions cannot be written for a diagnosis of type 2 diabetes if a patient does not have a confirmed diagnosis of type 2 diabetes

The airball comes as Novo scrambles to regain a majority share of the GLP-1 market, which it lost to Lilly in recent months

Ever since blockbuster weight-loss drugs like Wegovy and Zepbound went mainstream, calls to local poison control centers about side effects, incorrect dosing and other types of exposure are on a steep rise